Home/Pipeline/Prexigebersen (BP1001)

Prexigebersen (BP1001)

Acute Myeloid Leukemia (AML)

Phase 2Active

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase 2

Status

Active

Company

Bio-Path Holdings

About Bio-Path Holdings

Bio-Path Holdings is an oncology-focused biotech developing non-toxic, targeted cancer therapies for fragile patients ineligible for standard chemotherapy. Its core innovation is the DNAbilize® liposomal delivery platform, designed to concentrate antisense drugs at the tumor site while sparing healthy tissue. The company's strategy centers on advancing its lead asset, prexigebersen, in AML while exploring its platform's utility in solid tumors and other blood cancers through earlier-stage candidates. Recent leadership changes aim to revitalize clinical progress and corporate strategy.

View full company profile

Therapeutic Areas

Oncology Hematologic Cancer Solid Tumors

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
oNKord® (Inaleucel)	Glycostem	Phase 1/2a	Active